^
No biomarker
|
GBM
|
No biomarker
|
GBM
|
VAL-083 Sensitive: B - Late Trials
Kintara Therapeutics Press Release - 1 week (New B)
|
VAL-083 Sensitive: B - Late Trials
Kintara Therapeutics Press Release - 1 week - (New B)
|
BRAF fusion
|
Glioma
|
BRAF fusion
|
Glioma
|
DAY101 Sensitive: C3 – Early Trials
Day One Biopharmaceuticals Press Release - 2 weeks (New C3)
|
DAY101 Sensitive: C3 – Early Trials
Day One Biopharmaceuticals Press Release - 2 weeks - (New C3)
|
BRAF V600E
|
Glioma
|
BRAF V600E
|
Glioma
|
DAY101 Sensitive: C3 – Early Trials
Day One Biopharmaceuticals Press Release - 2 weeks (New C3)
|
DAY101 Sensitive: C3 – Early Trials
Day One Biopharmaceuticals Press Release - 2 weeks - (New C3)
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
PCV + thioguanine Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
|
PCV + thioguanine Sensitive: A2 - Guideline
NCCN - 3 weeks - (New A2)
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
carboplatin + vincristine Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
|
carboplatin + vincristine Sensitive: A2 - Guideline
NCCN - 3 weeks - (New A2)
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
carboplatin Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
|
carboplatin Sensitive: A2 - Guideline
NCCN - 3 weeks - (New A2)
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
cisplatin + etoposide IV Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
|
cisplatin + etoposide IV Sensitive: A2 - Guideline
NCCN - 3 weeks - (New A2)
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
everolimus Sensitive: A1 - Approval
|
everolimus Sensitive: A1 - Approval
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
No biomarker
|
Anaplastic Astrocytoma
|
No biomarker
|
Anaplastic Astrocytoma
|
temozolomide Sensitive: A1 - Approval
|
temozolomide Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
temozolomide Sensitive: A1 - Approval
|
temozolomide Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
teserpaturev Sensitive: A1 - Approval
|
teserpaturev Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
BRAF V600E
|
GBM
|
BRAF V600E
|
GBM
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
PCV Sensitive: A2 - Guideline
|
PCV Sensitive: A2 - Guideline
|
No biomarker
|
Anaplastic Astrocytoma
|
No biomarker
|
Anaplastic Astrocytoma
|
PCV Sensitive: A2 - Guideline
|
PCV Sensitive: A2 - Guideline
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
PCV Sensitive: A2 - Guideline
|
PCV Sensitive: A2 - Guideline
|
MGMT promoter methylation
|
GBM
|
MGMT promoter methylation
|
GBM
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Oligodendroglioma
|
No biomarker
|
Oligodendroglioma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
vemurafenib Sensitive: A2 - Guideline
|
vemurafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline
|
lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
lomustine Sensitive: A2 - Guideline
|
lomustine Sensitive: A2 - Guideline
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
regorafenib Sensitive: A2 - Guideline
|
regorafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
temozolomide gel Sensitive: A2 - Guideline
|
temozolomide gel Sensitive: A2 - Guideline
|
BRAF V600E
|
Glioma
|
BRAF V600E
|
Glioma
|
selumetinib Sensitive: A2 - Guideline
|
selumetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
cobimetinib Sensitive: A2 - Guideline
|
cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
vemurafenib Sensitive: A2 - Guideline
|
vemurafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
trametinib Sensitive: A2 - Guideline
|
trametinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
cobimetinib Sensitive: A2 - Guideline
|
cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
trametinib Sensitive: A2 - Guideline
|
trametinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Glioma
|
NTRK3 fusion
|
Glioma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Glioma
|
NTRK2 fusion
|
Glioma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Glioma
|
NTRK1 fusion
|
Glioma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
lomustine Sensitive: A2 - Guideline
|
lomustine Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Glioma
|
NTRK3 fusion
|
Glioma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Glioma
|
NTRK2 fusion
|
Glioma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Glioma
|
NTRK1 fusion
|
Glioma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
BRAF V600E
|
GBM
|
BRAF V600E
|
GBM
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
BRAF fusion
|
Glioma
|
BRAF fusion
|
Glioma
|
selumetinib Sensitive: A2 - Guideline
|
selumetinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
GBM
|
NTRK3 fusion
|
GBM
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
GBM
|
NTRK1 fusion
|
GBM
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
GBM
|
NTRK3 fusion
|
GBM
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
GBM
|
NTRK2 fusion
|
GBM
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
GBM
|
NTRK1 fusion
|
GBM
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
GBM
|
NTRK2 fusion
|
GBM
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
lomustine Sensitive: A2 - Guideline
|
lomustine Sensitive: A2 - Guideline
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
etoposide IV Sensitive: A2 - Guideline
|
etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
etoposide IV Sensitive: A2 - Guideline
|
etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
lapatinib Sensitive: A2 - Guideline
|
lapatinib Sensitive: A2 - Guideline
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
enzastaurin Sensitive: B - Late Trials
|
enzastaurin Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
DNX-2401 Sensitive: B - Late Trials
|
DNX-2401 Sensitive: B - Late Trials
|
H3.3K27M
|
Glioma
|
H3.3K27M
|
Glioma
|
ONC201 Sensitive: B - Late Trials
|
ONC201 Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
GDC-0084 Sensitive: B - Late Trials
|
GDC-0084 Sensitive: B - Late Trials
|
MGMT unmethylation
|
GBM
|
MGMT unmethylation
|
GBM
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
temozolomide gel Sensitive: B - Late Trials
|
temozolomide gel Sensitive: B - Late Trials
|
IDH1 R132H
|
Anaplastic Astrocytoma
|
IDH1 R132H
|
Anaplastic Astrocytoma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
MGMT promoter methylation
|
Anaplastic Astrocytoma
|
MGMT promoter methylation
|
Anaplastic Astrocytoma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
temozolomide gel Sensitive: B - Late Trials
|
temozolomide gel Sensitive: B - Late Trials
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
PCV Sensitive: B - Late Trials
|
PCV Sensitive: B - Late Trials
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
PCV Sensitive: B - Late Trials
|
PCV Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
GLR2007 Sensitive: B - Late Trials
|
GLR2007 Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
VB-111 Sensitive: B - Late Trials
|
VB-111 Sensitive: B - Late Trials
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
OKN-007 Sensitive: B - Late Trials
|
OKN-007 Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
CYNK-001 Sensitive: B - Late Trials
|
CYNK-001 Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
VBI-1901 Sensitive: B - Late Trials
|
VBI-1901 Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
RTA 744 Sensitive: B - Late Trials
|
RTA 744 Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
ST101 Sensitive: B - Late Trials
|
ST101 Sensitive: B - Late Trials
|
BRAF V600E
|
GBM
|
BRAF V600E
|
GBM
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
GBM
|
MSI-H/dMMR
|
GBM
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
BRAF V600
|
Ganglioglioma
|
BRAF V600
|
Ganglioglioma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600
|
Astrocytoma
|
BRAF V600
|
Astrocytoma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600
|
GBM
|
BRAF V600
|
GBM
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600
|
Anaplastic Astrocytoma
|
BRAF V600
|
Anaplastic Astrocytoma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
GBM
|
BRAF V600E
|
GBM
|
dabrafenib Sensitive: C1 - Off-label
|
dabrafenib Sensitive: C1 - Off-label
|
EGFR mutation
|
GBM
|
EGFR mutation
|
GBM
|
erlotinib Sensitive: C1 - Off-label
|
erlotinib Sensitive: C1 - Off-label
|
PD-L1 expression
|
GBM
|
PD-L1 expression
|
GBM
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
FGFR2 fusion
|
Glioma
|
FGFR2 fusion
|
Glioma
|
infigratinib Sensitive: C1 - Off-label
|
infigratinib Sensitive: C1 - Off-label
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
ivosidenib Sensitive: C1 - Off-label
|
ivosidenib Sensitive: C1 - Off-label
|
BRAF V600
|
Glioma
|
BRAF V600
|
Glioma
|
dabrafenib Sensitive: C1 - Off-label
|
dabrafenib Sensitive: C1 - Off-label
|
